Connor Clark & Lunn Investment Management Ltd. Has $51.42 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Connor Clark & Lunn Investment Management Ltd. grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 58,044 shares of the company's stock after buying an additional 3,644 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in Eli Lilly and Company were worth $51,424,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Peterson Financial Group Inc. purchased a new stake in Eli Lilly and Company in the third quarter worth approximately $27,000. MidAtlantic Capital Management Inc. bought a new position in Eli Lilly and Company during the 3rd quarter worth about $30,000. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company in the second quarter worth about $32,000. LGT Financial Advisors LLC acquired a new position in Eli Lilly and Company during the second quarter valued at $36,000. Finally, Morton Brown Family Wealth LLC raised its position in shares of Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company's stock worth $41,000 after acquiring an additional 15 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.13% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on LLY. Wells Fargo & Company upped their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an "overweight" rating in a research note on Friday, August 9th. BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an "outperform" rating in a research note on Friday, August 9th. Wolfe Research started coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 target price on the stock. Sanford C. Bernstein began coverage on Eli Lilly and Company in a report on Thursday, October 17th. They issued an "outperform" rating and a $1,100.00 target price for the company. Finally, Berenberg Bank raised their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a "buy" rating in a report on Wednesday, August 14th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,007.94.

Eli Lilly and Company Stock Up 3.2 %

LLY stock traded up $23.68 during trading on Wednesday, hitting $753.41. 5,118,295 shares of the stock traded hands, compared to its average volume of 3,185,653. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The stock has a market cap of $715.23 billion, a price-to-earnings ratio of 80.40, a price-to-earnings-growth ratio of 2.82 and a beta of 0.43. The firm's 50 day moving average is $875.60 and its two-hundred day moving average is $870.81.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to analysts' expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company's quarterly revenue was up 20.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.10 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.69%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.